MX2020005561A - Proteinas modificadas de union a adn. - Google Patents
Proteinas modificadas de union a adn.Info
- Publication number
- MX2020005561A MX2020005561A MX2020005561A MX2020005561A MX2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A
- Authority
- MX
- Mexico
- Prior art keywords
- dna binding
- binding proteins
- engineered dna
- engineered
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se proporcionan composiciones y métodos de uso de las mimas que comprenden una proteína de unión a ADN que no se presenta de manera natural que modula la expresión de un gen endógeno.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593824P | 2017-12-01 | 2017-12-01 | |
US201762610014P | 2017-12-22 | 2017-12-22 | |
US201862618966P | 2018-01-18 | 2018-01-18 | |
US201862641806P | 2018-03-12 | 2018-03-12 | |
US201862646198P | 2018-03-21 | 2018-03-21 | |
US201862664814P | 2018-04-30 | 2018-04-30 | |
US201862664817P | 2018-04-30 | 2018-04-30 | |
PCT/US2018/063498 WO2019109051A1 (en) | 2017-12-01 | 2018-11-30 | Engineered dna binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005561A true MX2020005561A (es) | 2020-10-12 |
Family
ID=66664596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005561A MX2020005561A (es) | 2017-12-01 | 2018-11-30 | Proteinas modificadas de union a adn. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200397917A1 (es) |
EP (1) | EP3717505A4 (es) |
JP (3) | JP7401432B2 (es) |
KR (1) | KR20200107949A (es) |
CN (2) | CN118345115A (es) |
AU (2) | AU2018375192B2 (es) |
BR (1) | BR112020010883A2 (es) |
CA (1) | CA3083765A1 (es) |
CL (1) | CL2020001451A1 (es) |
IL (1) | IL274926A (es) |
MA (1) | MA50942A (es) |
MX (1) | MX2020005561A (es) |
SG (1) | SG11202004926WA (es) |
TW (2) | TW202319538A (es) |
WO (1) | WO2019109051A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6923517B2 (ja) | 2015-10-09 | 2021-08-18 | ユニバーシティ・オブ・サザンプトン | 遺伝子発現の調節及び脱制御されたタンパク質発現のスクリーニング |
CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
EP3624858A4 (en) * | 2017-05-19 | 2021-06-23 | Encoded Therapeutics, Inc. | HIGH ACTIVITY REGULATORY ELEMENTS |
EP3673080B1 (en) | 2017-08-25 | 2023-10-18 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
CN117534769A (zh) | 2018-04-19 | 2024-02-09 | 加利福尼亚大学董事会 | 用于基因编辑的组合物和方法 |
BR112021024055A2 (pt) * | 2019-05-29 | 2022-02-08 | Encoded Therapeutics Inc | Composições e métodos para a regulação seletiva de gene |
CA3147643A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression |
GB201913974D0 (en) * | 2019-09-27 | 2019-11-13 | King S College London | Vector |
CA3166986A1 (en) * | 2020-01-07 | 2021-07-15 | Sumitomo Pharma Co., Ltd. | Therapeutic agent for tauopathies |
CA3173647A1 (en) | 2020-05-11 | 2021-11-18 | Isabel AZNAREZ | Opa1 antisense oligomers for treatment of conditions and diseases |
EP4150083A1 (en) * | 2020-05-13 | 2023-03-22 | F. Hoffmann-La Roche AG | Oligonucleotide agonists targeting progranulin |
WO2022125420A1 (en) * | 2020-12-09 | 2022-06-16 | City Of Hope | Compounds and methods to treat cystic fibrosis |
CN115074389A (zh) * | 2022-06-13 | 2022-09-20 | 华南农业大学 | 稳定表达鸭坦布苏病毒ns1蛋白的细胞系的构建方法及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030104526A1 (en) * | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7329728B1 (en) * | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
ES2409080T3 (es) * | 2001-01-22 | 2013-06-24 | Sangamo Biosciences Inc. | Proteínas de unión con dedos de zinc modificadas |
ATE441712T1 (de) * | 2001-02-21 | 2009-09-15 | Novartis Pharma Gmbh | Die nukleotidsequenz ann bindende zink-finger domänen |
EP1481087A4 (en) * | 2002-02-07 | 2005-12-21 | Scripps Research Inst | ZINC FINGER LIBRARIES |
WO2009060316A2 (en) * | 2007-09-14 | 2009-05-14 | The Governors Of The University Of Alberta | Hepatitis b virus-binding polypeptides and methods of use thereof |
BR112014005234A2 (pt) * | 2011-09-06 | 2017-04-11 | Curna Inc | tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas |
KR102530118B1 (ko) * | 2012-07-25 | 2023-05-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유도 dna 결합 단백질 및 게놈 교란 도구 및 이의 적용 |
AR095982A1 (es) * | 2013-04-03 | 2015-11-25 | Aliophtha Ag | Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico |
TW201514201A (zh) * | 2013-04-03 | 2015-04-16 | Aliophtha Ag | 調控核受體之人工轉錄因子及其治療用途 |
US10076574B2 (en) * | 2013-10-25 | 2018-09-18 | Wayne State University | Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming |
WO2015153760A2 (en) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
US20180346531A1 (en) * | 2015-09-15 | 2018-12-06 | Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
CN116059236A (zh) * | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
CA3016314A1 (en) * | 2016-03-02 | 2017-09-08 | Julianne REIDERS | Therapy for frontotemporal dementia |
WO2017180915A2 (en) * | 2016-04-13 | 2017-10-19 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
-
2018
- 2018-11-30 CN CN202410447378.XA patent/CN118345115A/zh active Pending
- 2018-11-30 MX MX2020005561A patent/MX2020005561A/es unknown
- 2018-11-30 AU AU2018375192A patent/AU2018375192B2/en active Active
- 2018-11-30 WO PCT/US2018/063498 patent/WO2019109051A1/en active Application Filing
- 2018-11-30 EP EP18884285.0A patent/EP3717505A4/en active Pending
- 2018-11-30 CA CA3083765A patent/CA3083765A1/en active Pending
- 2018-11-30 KR KR1020207018993A patent/KR20200107949A/ko not_active Application Discontinuation
- 2018-11-30 BR BR112020010883-9A patent/BR112020010883A2/pt unknown
- 2018-11-30 JP JP2020529582A patent/JP7401432B2/ja active Active
- 2018-11-30 MA MA050942A patent/MA50942A/fr unknown
- 2018-11-30 CN CN201880088375.4A patent/CN111727259B/zh active Active
- 2018-11-30 SG SG11202004926WA patent/SG11202004926WA/en unknown
- 2018-12-03 TW TW111138440A patent/TW202319538A/zh unknown
- 2018-12-03 TW TW107143330A patent/TWI835761B/zh active
-
2020
- 2020-05-25 IL IL274926A patent/IL274926A/en unknown
- 2020-05-28 US US16/886,129 patent/US20200397917A1/en active Pending
- 2020-05-29 CL CL2020001451A patent/CL2020001451A1/es unknown
-
2022
- 2022-09-14 JP JP2022145839A patent/JP2022171792A/ja active Pending
-
2023
- 2023-12-20 AU AU2023285810A patent/AU2023285810A1/en active Pending
-
2024
- 2024-03-19 JP JP2024043454A patent/JP2024069591A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3083765A1 (en) | 2019-06-06 |
CN111727259B (zh) | 2024-04-19 |
US20200397917A1 (en) | 2020-12-24 |
KR20200107949A (ko) | 2020-09-16 |
WO2019109051A1 (en) | 2019-06-06 |
AU2018375192A1 (en) | 2020-07-02 |
CL2020001451A1 (es) | 2020-11-06 |
TW201925474A (zh) | 2019-07-01 |
BR112020010883A2 (pt) | 2020-11-10 |
TWI835761B (zh) | 2024-03-21 |
MA50942A (fr) | 2020-10-07 |
JP2024069591A (ja) | 2024-05-21 |
EP3717505A4 (en) | 2021-12-01 |
CN118345115A (zh) | 2024-07-16 |
CN111727259A (zh) | 2020-09-29 |
IL274926A (en) | 2020-07-30 |
AU2023285810A1 (en) | 2024-01-18 |
SG11202004926WA (en) | 2020-06-29 |
EP3717505A1 (en) | 2020-10-07 |
AU2018375192B2 (en) | 2023-11-09 |
JP2021505133A (ja) | 2021-02-18 |
TW202319538A (zh) | 2023-05-16 |
JP7401432B2 (ja) | 2023-12-19 |
JP2022171792A (ja) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005561A (es) | Proteinas modificadas de union a adn. | |
WO2018160754A3 (en) | Inducible monovalent antigen binding protein | |
IL281783A (en) | SIRPa type binding proteins and methods of using them | |
MX2020003596A (es) | Composiciones de acido nucleico-polipeptido y usos de las mismos. | |
MX2020008542A (es) | Composiciones y métodos para el suministro de proteínas membranales. | |
EP3436068A4 (en) | BINDING PROTEINS AND METHOD FOR USE THEREOF | |
ZA201901592B (en) | Recombinant binding proteins and their use | |
MY191944A (en) | Binding proteins and methods of use thereof | |
EP3324996A4 (en) | GDF11 BINDING PROTEINS AND USES THEREOF | |
EP3256495A4 (en) | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins | |
IL268884A (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
MA47465A (fr) | Protéines fixant le bcma, le nkg2d et le cd16 | |
IL279201A (en) | Multispecific binding proteins and methods of using them | |
EP3444270A4 (en) | NEW NATURAL PROTEIN AND ITS APPLICATION | |
SA518391831B1 (ar) | تركيبات وطرق لخفض تعبير البروتين تاو | |
EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
EP3445394A4 (en) | ALK7 BINDING PROTEINS AND USES THEREOF | |
IL281972A (en) | Methods and compositions for modulation of tau proteins | |
WO2017040329A3 (en) | Peptides binding to bfl-1 | |
MX2017016842A (es) | Proteinas de fijacion multiespecifica. | |
EP3630967B8 (en) | Protease and binding polypeptide for o-glycoproteins | |
NZ731491A (en) | Cd83 binding proteins and uses thereof | |
EP3700571A4 (en) | ALK7-BINDING PROTEINS AND USES THEREOF | |
MX2018011193A (es) | Proteinas derivadas de alfa-1-microglobulina novedosas y su uso. |